Literature DB >> 9542734

Biological and clinical MRS at ultra-high field.

H P Hetherington1, J W Pan, W J Chu, G F Mason, B R Newcomer.   

Abstract

The advantages of performing spectroscopic studies at higher field strengths include increased SNR, improved spectral resolution for J-coupled resonances, and improvements in the selectivity of spectral editing schemes. By using pulse sequences that minimize the required echo time, refocus J-evolution, employ low peak B1 requiring pulses and take advantage of spectroscopic imaging methods, these advantages can also be utilized in clinical applications of spectroscopy at high field. In addition to the static measurements measurements of N-acetyl aspartate (NAA), creatine (CR) and choline (CH) which can be performed at 1.5 T, high resolution measurements of glutamate, glutamine, GABA and the incorporation of 13C labeled glucose into glutamate are possible with improved spatial and spectral resolution. These methods have been utilized in patients with seizure disorders and multiple sclerosis to identify, characterize and map the metabolic changes associated with these diseases and their treatment.

Entities:  

Mesh:

Year:  1997        PMID: 9542734     DOI: 10.1002/(sici)1099-1492(199712)10:8<360::aid-nbm477>3.0.co;2-8

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  18 in total

Review 1.  Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer.

Authors:  J Kurhanewicz; D B Vigneron; S J Nelson
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

2.  Topiramate raises anterior cingulate cortex glutamine levels in healthy men; a 4.0 T magnetic resonance spectroscopy study.

Authors:  Constance M Moore; Megan Wardrop; Blaise deB Frederick; Perry F Renshaw
Journal:  Psychopharmacology (Berl)       Date:  2006-08-31       Impact factor: 4.530

Review 3.  Proton MR spectroscopy of the brain at 3 T: an update.

Authors:  Alfonso Di Costanzo; Francesca Trojsi; Michela Tosetti; Timo Schirmer; Silke M Lechner; Teresa Popolizio; Tommaso Scarabino
Journal:  Eur Radiol       Date:  2007-01-18       Impact factor: 5.315

4.  Doubly selective multiple quantum chemical shift imaging and T(1) relaxation time measurement of glutathione (GSH) in the human brain in vivo.

Authors:  In-Young Choi; Phil Lee
Journal:  NMR Biomed       Date:  2012-06-22       Impact factor: 4.044

Review 5.  Multiple sclerosis: the role of MR imaging.

Authors:  Y Ge
Journal:  AJNR Am J Neuroradiol       Date:  2006 Jun-Jul       Impact factor: 3.825

6.  Determining the in vivo transverse relaxation time of GABA in the human brain at 7T.

Authors:  Jarunee Intrapiromkul; He Zhu; Ying Cheng; Peter B Barker; Richard A E Edden
Journal:  J Magn Reson Imaging       Date:  2012-12-13       Impact factor: 4.813

7.  Occipital cortical proton MRS at 4 Tesla in human moderate MDMA polydrug users.

Authors:  Ronald L Cowan; Nicolas R Bolo; Mary Dietrich; Erica Haga; Scott E Lukas; Perry F Renshaw
Journal:  Psychiatry Res       Date:  2007-06-18       Impact factor: 3.222

8.  Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T.

Authors:  Kejal Kantarci; Glenn Reynolds; Ronald C Petersen; Bradley F Boeve; David S Knopman; Steven D Edland; Glenn E Smith; Robert J Ivnik; Eric G Tangalos; Clifford R Jack
Journal:  AJNR Am J Neuroradiol       Date:  2003-05       Impact factor: 3.825

9.  N-acetylaspartate (NAA) correlates inversely with cannabis use in a frontal language processing region of neocortex in MDMA (Ecstasy) polydrug users: a 3 T magnetic resonance spectroscopy study.

Authors:  Ronald L Cowan; James M Joers; Mary S Dietrich
Journal:  Pharmacol Biochem Behav       Date:  2008-11-13       Impact factor: 3.533

10.  Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker.

Authors:  H Watanabe; H Fukatsu; M Katsuno; M Sugiura; K Hamada; Y Okada; M Hirayama; T Ishigaki; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-01       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.